Arcellx — Investor Presentation (December 2022)
37 slides from Arcellx's investor presentation, Dec 12, 2022
Slide 1: Corporate Presentation December 2022
Exhibit 99.1 Corporate Presentation December 2022
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, that are based on our management’s beliefs and assumptions and on informati
Slide 3: Reimagining Cell Therapy
Reimagining Cell Therapy Platform Partnered Lead Novel Synthetic Positive Preliminary Built for Potential Program Binding Domain Clinical Results Success ARC-SparX Phase 1 clinical Strong investor base Combining potential best in Demonstrated 100% overall Single-infusion ddCAR and trial in multiple
Slide 4: Maximizing the Value of MM Opportunity with Kite Partnership
Maximizing the Value of MM Opportunity with Kite Partnership Positioned for Leadership Long-term Value Global Collaboration in CAR-T Space ‣ Arcellx to receive $225M upfront ‣ Combining a potential best-in-‣ Co-development and co- payment and $100M equity class therapy with Kite’s commercialization
Slide 5: Kite – The Cell Therapy Partner of Choice
Kite – The Cell Therapy Partner of Choice Manufacturing Commercial Pipeline Investment ‣ Largest dedicated in-house global cell ‣ More than 11,000 patients treated ‣ Kite may integrate complementary therapy manufacturing network (clinical trial and commercial patients) technologies with Arcellx’s pl
Slide 6: Kite Partnership Summary
Kite Partnership Summary ‣ Topline economics: ‒ Total upfront consideration: $325Mn ‣ Upfront payment: $225Mn ‣ Equity Investment (3,478,261 shares): $100Mn ‒ Contingent milestones across all programs ‣ Up to $335M, $635M and $508M for each ddBCMA, next-generation autologous, and non-autologous prod
Slide 7: Partnership Structure Creates Value While Maximizing Runway
Partnership Structure Creates Value While Maximizing Runway ‣ Limiting outflows of capital related to CMC: CMC commercial readiness are borne by Kite; leveraging Kite’s prior investments in CMC helps us realize downstream benefits in COGS and timelines to scale-up to meet demand ‣ Reducing costs pri
Slide 8: Our Mission
OUR MISSION Advance humanity by engineering cell therapies that are safer, more effective, and more broadly accessible
Slide 9: Multiple Myeloma is a Significant Market Opportunity
Multiple Myeloma is a Significant Market Opportunity 3rd most Impacting Limited Therapies common 100,000 patients comprise $18B global blood cancer annually market today Growing opportunity Incurable for CAR-T solutions Total addressable disease with as more effective market of $10B life expectancy
Slide 10: A Rich Development Pipeline with Growth in Mind
A Rich Development Pipeline with Growth in Mind Stage of Development Discovery/ Indication Platform Phase 1 Phase 2 Phase 3 Partnered Preclinical Clinical and Preclinical Pipeline ddCAR iMMagine-1 pivotal/ CART-ddBCMA Multiple iMMagine-2 (earlier lines) / CART-ddBCMA ddCAR Myeloma * ACLX-001: BCMA A
Slide 11: Binding Domain Differentiated by Size and Stability
Binding Domain Differentiated by Size and Stability Bi-Valent 1 2 TCR scFv D-Domain 3 Camelid VHh (50kDa) (25kDa) (8kDa) (25kDa) 41BB CD3z CD3z CD3z 1 Chan, KF. et al. 2018.,Nat Commun 9:1026-1026 2 Bjerragaard-Anderson, K., et al 2018. Sci. Rep., 8:10836-10836. 3 https://commons.wikimedia.org/wiki/
Slide 12: D-Domain Designed To Enhance Safety, Efficacy, and Availability
D-Domain Designed To Enhance Safety, Efficacy, and Availability D-Domain Hydrophobic Core & Stable Low Tonic Signaling High Transduction Efficiency High Surface Expression Potentially improved binding Lower dose may lead to lower toxicity Reduced T cell exhaustion The simple structure of D-Domains P
Slide 13: D-Domain Technology: Expansive Platform
D-Domain Technology: Expansive Platform ddCAR Classical Single Infusion CAR-T ARC-SparX Dosable CAR-T • Ability to leverage autologous or allogeneic strategies • Therapeutic potential across liquid and solid tumors as well as non-oncology indications 13 Arcellx Corporate Presentation | December 2022
Slide 14: 2022 Achievements and Upcoming Milestones
2022 Achievements and Upcoming Milestones Multiple Myeloma Projected Date ddCAR- FDA End-of-Phase 1 meeting 4Q21 ddCAR- ASH 2021 Data Update 4Q21 ARC-SparX - Initiate Phase 1 Enrollment in ACLX-001 1H22 ddCAR- Present Data Update 1H22 ddCAR- Present Data Update Q422 ddCAR- Initiate Pivotal Study YE2
Slide 15: Our Lead Clinical Program
OUR LEAD CLINICAL PROGRAM Looking at best-in-class potential for patient outcomes for those who previously failed multiple lines of multiple myeloma therapy
Slide 16: Best-in-Class Potential
Best-in-Class Potential Phase 1 Study Preliminary Results 100% ORR 115M (+/- 10) Cells 0% Grade 3 CRS 71% CR/sCR RP2D RP2D Overall response rate (ORR) per Ongoing Phase 1 expansion at Toxicities including CRS and 100 (+/- 20) million CAR+ T cells IMWG across both dose levels; deep ICANS have been ma
Slide 17: Background and Methods
Background and Methods CART-ddBCMA is an autologous CAR-T 1,2 containing a novel synthetic protein binding domain (non-scFv) engineered to reduce the risk of immunogenicity and is highly stable Phase 1 first-in-human trial has completed enrollment of relapsed and/or refractory myeloma • Prior IMiD,
Slide 18: Patient Disposition
Patient Disposition Enrolled and Leukapheresed n=40 Successful Manufacture of CART-ddBCMA n=40 Discontinued: Active infection, n=1 Lymphodepletion n=39 Discontinued: Active infection, n=1 Total Dosed n=38 6 6 DL1, 100x10 CAR+ cells DL2, 300x10 CAR+ cells n=32 n=6 Dose escalation Expansion cohort Dos
Slide 19: Patient Demographics (as of Oct 2022)
Patient Demographics (as of 31 Oct 2022) Dose Level 1 Dose Level 2 Total Characteristics 100 million CAR-T 300 million CAR-T (n=38) (n=32) (n=6) Age, median (min - max) 66 (44 - 76) 60 (52 - 65) 66(44 - 76) 18 Male (56%) 5 Male (83%) 23 Male (61%) Gender 14 Female (44%) 1 Female (17%) 15 Female (39%
Slide 20: CART-ddBCMA Manufacturability: Reliable Process, Consistent Product
CART-ddBCMA Manufacturability: Reliable Process, Consistent Product Cell Viability CAR Positivity 100% 100% 90% Low inter-patient 80% 80% High cell viability: + variability in CAR Acceptance Limit 70% median 98% cells: median 70% 60% 60% viable cells + 50% CAR cells 40% 40% 30% Acceptance Limit 20%
Slide 21: Potential for Best-in-Class Treatment
Potential for Best-in-Class Treatment 0 3 6 9 12 15 18 21 24 27 30 33 Best ORR Best MRD -6 sCR 10 1 sCR NE 2 -6 sCR 10 3 PR POS 4 -6 sCR 10 5 PR NE 6 -5 CR 10 7 -6 sCR 10 8 -6 VGPR 10 9 CR NE 10 -6 sCR 10 11 -4 CR 10 12 -6 sCR 10 13 -6 sCR 10 14 -5 CR 10 15 -6 sCR 10 16 -6 sCR 10 17 -6 VGPR 10 18 sC
Slide 22: CART-ddBCMA Responses Deepen Over Time
CART-ddBCMA Responses Deepen Over Time 8% 9% 11% 13% 100% 12% 6% 20% 18% 75% 50% 81% 80% 71% 71% 25% 0% 1 month; (n=38) 6 months; (n=35) 12 months; (n=25) 18 months; (n=16) CR/sCR VGPR PR Minimum months since infusion (M) 1 6 12 18 38 35 25 16 Sample Size (n)* Median Follow-up (mo) 15.0 16.4 18.9 22
Slide 23: Responses in Subgroups
Responses in Subgroups CR/sCR VGPR 9% 10% 11% 14% 100% 15% 9% 15% 9% PR 18% 75% 50% 85% 82% 77% 75% 71% 25% 0% All Subjects; (n=38) High Risk; (n=22) EMD; (n=13) High Risk Age ≥65; (n=20) Cytogenetics; (n=11) Patients n 6-month PFS % 12-month PFS % 18-month PFS % (%) (95% CI) (95% CI) (95% CI) 38 91
Slide 24: CART-ddBCMA: 100% ORR, High CR Rate, and Durable Responses
CART-ddBCMA: 100% ORR, High CR Rate, and Durable Responses Demonstrate Potential for Best-in-Class Treatment CART-ddBCMA LEGEND-2 CARTITUDE-1 Minimum follow-up (mo.) 1 18 1 1.5 13.5 (est.) Sample Size (n) 38 16 57 97 Median Follow-up (mo.) 15.0 22.9 8 12.4 24 EMD % 34% 50% 30% 13% 13% ORR 100% 100%
Slide 25: Adverse Event Profile (as of Oct 2022)
Adverse Event Profile (as of 31 Oct 2022) Grade 3/4 AEs (non-CRS/ICANS) CAR-T-associated AEs 100 million 300 million ≥5% after cell infusion Per ASTCT criteria (N=32) (N=6) (N=38) Hematologic Grade 1/2 Grade 3 Grade 1/2 Grade 3 Cytokine Release Neutrophil count decreased 29 (76.3%) Syndrome (CRS) 30
Slide 26: CART-ddBCMA Phase 1: Conclusions
CART-ddBCMA Phase 1: Conclusions CART-ddBCMA utilizes a novel, synthetic highly stable binding domain • 2 dose levels studied (100 and 300 million CAR+ T-cells); MTD not reached • Consistency in manufacturing (100% success) highlighted by high CAR-T cell viability, low inter-patient variability in C
Slide 27: Our Technology
OUR TECHNOLOGY With our novel synthetic binding scaffold, we are supercharging how the world treats diseases, by engineering transformative treatment platforms
Slide 28: D-Domain Designed To Enhance Safety, Efficacy, and Availability
D-Domain Designed To Enhance Safety, Efficacy, and Availability D-Domain Hydrophobic Core & Stable Low Tonic Signaling High Transduction Efficiency High Surface Expression Lower dose may lead to lower toxicity Potentially improved binding Reduced T cell exhaustion . 180000 160000 140000 Donor 1 1200
Slide 29: Our ARC-SparX Platform Powered by the D-Domain
Our ARC-SparX Platform Powered by the D-Domain Novel CAR-T modular solution that is CONTROLLABLE and ADAPTABLE Multiple SparX for Patient X Single infusion of ARC-T Periodic intravenous injection or Continue, switch, in outpatient setting self-administration by subcutaneous or stop… injection of Spa
Slide 30: Controllable and Adaptable: The ARC-SparX Advantage
Controllable and Adaptable: The ARC-SparX Advantage Controllable activity to enhance safety for Adaptable therapy to personalize the potential increased access to outpatient approach with libraries of SparX including and/or community-based settings logic gated bi-specific formats Control of ARC-T po
Slide 31: A Rich Development Pipeline with Growth in Mind
A Rich Development Pipeline with Growth in Mind Stage of Development Discovery/ Indication Platform Phase 1 Phase 2 Phase 3 Partnered Preclinical Clinical and Preclinical Pipeline ddCAR iMMagine-1 pivotal/ CART-ddBCMA Multiple iMMagine-2 (earlier lines) / CART-ddBCMA ddCAR Myeloma * ACLX-001: BCMA A
Slide 32: Our Business
OUR BUSINESS Our team blends vision with results, to achieve the kind of technological, mission-critical breakthroughs that reward investment and improve lives
Slide 33: Our Global Patent Portfolio
Our Global Patent Portfolio Worldwide patent coverage with issued and pending applications in major market/manufacturing countries 16+ Patents Granted Worldwide Broad Patent Coverage, including: ‣ Developing D-Domain Libraries ‣ Therapeutic and other use of D-Domains ‣ Adapter Platforms 50+ Worldwid
Slide 34: A Team United Under a Shared Mission
A Team United Under a Shared Mission Maryam Abdul- Rami Elghandour Kate Aiken Michael Dombeck Aileen Fernandes Michelle Gilson Chris Heery, MD Narinder Singh Kareem, JD, MS Neeraj Teotia David Tice, PhD Doug Alleavitch Brad Gliner Myesha Lacy Shashi Kaithamana, PhD Brian Murphy, PhD 34 Arcellx Corpo
Slide 35: Reimagining Cell Therapy with Every Cell of Our Being
Reimagining Cell Therapy with Every Cell of Our Being Technology & IP Team Strategy CMC Pipeline Wholly owned Aligned leaders building a Focused on attractive Foundations for scale and Exploring new frontiers differentiated technology diverse best place to work markets commercial launch including AM
Slide 36: Our Mission
OUR MISSION Advance humanity by engineering cell therapies that are safer, more effective, and more broadly accessible
Slide 37: Thank you
A Thank you